Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Emerging Infectious Disease Diagnostics Market Size, Value And Growth Trends Through 2030

The market for diagnostics of emergent infectious diseases has experienced robust expansion recently, projected to increase from $24.34 billion in 2025 to $26.75 billion in 2026, reflecting a compound annual growth rate of 9.9%. This upward trajectory during the past period is a consequence of several factors, including a greater number of infectious disease outbreaks, the broadening scope of public health monitoring initiatives, heightened financial commitments to laboratory facilities, a growing need for swift diagnostic tools, and the evolution of molecular testing methodologies.

Anticipate significant expansion within the realm of emerging infectious disease diagnostics, projecting a market valuation to reach $38.54 billion by 2030, fueled by a compound annual growth rate of 9.6%. This upward trajectory is largely propelled by a heightened emphasis on pandemic preparedness, the increasing utilization of advanced sequencing technologies for diagnostic purposes, the broader implementation of decentralized testing strategies, the growing incorporation of artificial intelligence in diagnostic analysis, and augmented governmental investment in disease surveillance efforts. Key developments expected to shape this period include a greater emphasis on deploying rapid molecular diagnostic systems, a surge in the adoption of point-of-care testing, enhanced integration of genomic surveillance capabilities, the wider availability of multiplex diagnostic tests, and a more pronounced focus on the early detection of disease outbreaks.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20548&type=smp

Emerging Infectious Disease Diagnostics Market Growth Momentum: Which Factors Are Influencing Demand?

An increase in zoonotic diseases, which are transferable from animals to people through bacteria, viruses, parasites, or fungi, is anticipated to fuel the expansion of the emerging infectious disease diagnostics market. This surge in zoonotic infections is largely attributed to greater contact between humans and wildlife, the destruction of natural habitats, and worldwide travel, all of which contribute to the spread of pathogens across different species. Diagnostic tools for emerging infectious diseases play a crucial role in addressing zoonotic disease challenges by facilitating the early identification and precise characterization of disease-causing agents. This allows for swift medical responses, successful treatments, and more effective control of disease dissemination, ultimately curbing the transmission from animal populations to humans. Illustratively, data from the Centers for Disease Control and Prevention revealed that by June 2025, the United States had recorded 2,770 human cases of arboviral diseases across 48 states and the District of Columbia in 2023, a significant jump from the 1,247 cases reported in 2022. These figures included 2,022 hospitalizations, representing 73% of cases, and 208 fatalities, or 8%, with West Nile virus being the predominant domestically reported arboviral illness in 2023, accounting for 2,628 cases, or 95% of the total. Consequently, the escalating prevalence of zoonotic diseases serves as a key driver for the emerging infectious disease diagnostics market.

Emerging Infectious Disease Diagnostics Market Segment Outlook: Which Categories Are Expanding The Fastest?

The emerging infectious disease diagnostics market covered in this report is segmented –

1) By Infection Type: Viral, Bacterial, Fungal, Other Infections

2) By Disease Type: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Other Disease Types

3) By Technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, Other Technologies

4) By Application: Laboratory Testing, Point-of-Care Testing

5) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Other End-Users

Subsegments:

1) By Viral: Respiratory Viruses, Hepatitis Viruses, HIV and Retroviruses, Arboviruses, Herpesviruses, Gastrointestinal Viruses, Emerging Viral Infections

2) By Bacterial: Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA), Escherichia Coli (E. coli) Infections, Streptococcus and Pneumococcus Infections, Clostridium Infections, Neisseria, Emerging Drug-Resistant Bacteria

3) By Fungal: Candidiasis, Aspergillosis, Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Pneumocystis Pneumonia (PCP), Emerging Fungal Infections

4) By Other Infections: Parasitic Infections, Protozoan Infections, Prion Diseases, Helminthic Infections, Non-Pathogenic or Environmental Infections

Emerging Infectious Disease Diagnostics Market Trends Reshaping Industry Growth

Major players within the burgeoning market for emerging infectious disease diagnostics are concentrating their efforts on pioneering novel approaches, like temperature-activated generation of signal (TAGS) technology, to bolster rapid detection, facilitate high-volume screening, and elevate response mechanisms during outbreaks. This sophisticated TAGS technology represents a cutting-edge multiplex PCR technique that employs regulated temperature activation to produce optical signals for the simultaneous identification of various pathogens from an individual sample. This facilitates critical functions such as comprehensive syndromic testing, accelerated processing durations, and streamlined laboratory operations. As an illustration, in September 2024, the Switzerland-headquartered diagnostics and biotechnology firm, F. Hoffmann-La Roche AG, introduced the cobas Respiratory flex test. This molecular diagnostic, powered by TAGS, is engineered to identify up to 12 prevalent respiratory viruses from a single patient specimen, offering automated high-throughput examination, adaptable pathogen panel customization, and seamless integration with the cobas 5800, 6800, and 8800 platforms. Consequently, the cobas Respiratory flex enhances the prompt identification of infectious agents, fortifies clinical judgment, and contributes to improved readiness against emerging disease dangers.

Emerging Infectious Disease Diagnostics Market Key Companies And Competitive Benchmarking

Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.

Access The Complete Emerging Infectious Disease Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/emerging-infectious-disease-diagnostics-global-market-report

Emerging Infectious Disease Diagnostics Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the emerging infectious disease diagnostics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model